Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
A Study Comparing the Analgesic Efficacy and Safety of Extended Release Hydrocodone/Acetaminophen (Vicodin® CR)and Placebo in Subjects With Osteoarthritis
This study has been completed.
Sponsored by: Abbott
Information provided by: Abbott
ClinicalTrials.gov Identifier: NCT00404183
  Purpose

The purpose of this study is to evaluate the effectiveness (level of pain control) and safety of the administration of Extended Release Hydrocodone/Acetaminophen with placebo over a 5-week dosing period in patients with osteoarthritis.


Condition Intervention Phase
Pain
Drug: Extended-Release Hydrocodone/Acetaminophen (Vicodin® CR)
Phase II

MedlinePlus related topics: Osteoarthritis
Drug Information available for: Acetaminophen Hydrocodone Hydrocodone bitartrate Vicodin
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A Randomized, Multi-Center, Double-Blind Study Comparing the Analgesic Efficacy and Safety of Extended Release Hydrocodone/Acetaminophen (Vicodin® CR)and Placebo in Subjects With Osteoarthritis

Further study details as provided by Abbott:

Primary Outcome Measures:
  • Pain intensity difference from baseline to final assessment using the VAS scale (100 mm, 0 being "no pain" and 100 being "worst pain imaginable").

Secondary Outcome Measures:
  • WOMAC Osteoarthritis Index
  • MOS Sleep Scale
  • Pain Intensity difference as assessed by the Subject’s Assessment of Arthritis Pain Intensity by VAS (at each scheduled assessment other than final)
  • Subject’s Global Assessment of Study Drug
  • Subject’s and Physician’s Global Assessment of Arthritis Status
  • Time-interval weighted measure of pain intensity difference from baseline (area under the curve) divided by the maximum benefit possible for an individual subject
  • Treatment responders
  • SF-36v2TM Health Status Survey (Acute)

Estimated Enrollment: 120
Study Start Date: August 2004
Estimated Study Completion Date: March 2005
  Eligibility

Ages Eligible for Study:   21 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Males or females ages 21 to 75
  • Has osteoarthritis of the hip or knee
  • Requires therapeutic doses of medications for osteoarthritis
  • If female, must be of non-childbearing potential or practicing birth control
  • Has sufficient pain to justify the use of round-the-clock opioids

Exclusion Criteria:

  • Has received certain types of procedures or received certain medications for osteoarthritis within a specific timeframe
  • Has certain medical conditions which may interfere with pain assessments
  • Is allergic to or has a serious reaction to hydrocodone, other opioids, or acetaminophen
  • Has had certain infections, injuries or illnesses within the last month
  • Has had major abdominal surgery, certain diseases that may cause intestinal narrowing, or has a history of constipation, diarrhea or nausea and vomiting
  • Is receiving chemotherapy, or has been diagnosed with certain cancers within the past 5 years
  • Has a history of major psychiatric disorders or requires treatment with certain drugs for depression
  • Cannot discontinue pain medications, even for a short time, prior to the study start
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00404183

Sponsors and Collaborators
Abbott
Investigators
Study Director: Rita Jain, MD Abbott
  More Information

Study ID Numbers: M03-643
Study First Received: November 26, 2006
Last Updated: July 23, 2007
ClinicalTrials.gov Identifier: NCT00404183  
Health Authority: United States: Food and Drug Administration

Keywords provided by Abbott:
Pain associated with osteoarthritis

Study placed in the following topic categories:
Osteoarthritis
Joint Diseases
Pain
Rheumatic Diseases
Naphazoline
Oxymetazoline
Musculoskeletal Diseases
Phenylephrine
Guaifenesin
Arthritis
Hydrocodone
Phenylpropanolamine
Acetaminophen

Additional relevant MeSH terms:
Respiratory System Agents
Physiological Effects of Drugs
Central Nervous System Depressants
Narcotics
Pharmacologic Actions
Analgesics, Non-Narcotic
Sensory System Agents
Therapeutic Uses
Analgesics
Peripheral Nervous System Agents
Antitussive Agents
Central Nervous System Agents
Analgesics, Opioid

ClinicalTrials.gov processed this record on January 14, 2009